Olivia A Wackowski1, Richard J O'Connor2, Jennifer L Pearson3. 1. Rutgers Center for Tobacco Studies, Department of Health Behavior, Society and Policy, Rutgers School of Public Health, Rutgers University, New Brunswick, NJ. 2. Department of Health Behavior, Roswell Park Cancer Institute, Buffalo, NY. 3. Department of Health Administration and Policy, School of Community Health Sciences, University of Nevada, Reno, NV.
Abstract
INTRODUCTION: Based on arguments for harm reduction and health benefits, tobacco companies in the United States can apply for regulatory authorization to make "modified risk tobacco product" (MRTP) marketing claims. The impact of future MRTP claims may depend on whether they are noticed, believed, and lead to smokers switching products. This study provides baseline data about smokers' exposure to perceived MRTP claims ahead of any MRTP authorizations. AIMS AND METHODS: We analyzed measures from Wave 3 of the US-based Population Assessment of Tobacco and Health (PATH) study which asked smokers to indicate if they had seen any e-cigarettes, snus, or other smokeless tobacco (SLT) products that claim to be "less harmful" in the past 12 months, and their likelihood of using products with these claims in the next 30 days. RESULTS: Significantly fewer smokers noted having seen snus (5.1%) or other SLT (5.6%) with "less harmful" claims compared with e-cigarettes (29.1%). For each product, the prevalence of MRTP claim exposure was higher among smokers who perceived the product to be less harmful than smoking, who currently used the product, and who had higher rates of tobacco advertising exposure at the point of sale. Among smokers who noticed products with "less harmful" claims, about one-quarter said they would use them in the future (24%-27%). CONCLUSIONS: Ahead of any Food & Drug Administration (FDA) authorization for MRTP claims, some smokers already perceive exposure to "less harmful" claims for e-cigarettes, but few do for SLT. MRTP claims may motivate some smokers to use these products. IMPLICATIONS: This study provides new baseline data about smokers' perceived exposure to MRTP claims in the United States ahead of any regulatory claim authorization. Using data from Wave 3 of the US PATH study, we found that some smokers already perceive exposure to "less harmful" claims for e-cigarettes (29%), but few do for SLT (5%-6%). Among smokers who noticed products with "less harmful" claims, about one-quarter said they would use them in the future (24%-27%), suggesting MRTP claims may motivate some smokers to use products described as "less harmful."
INTRODUCTION: Based on arguments for harm reduction and health benefits, tobacco companies in the United States can apply for regulatory authorization to make "modified risk tobacco product" (MRTP) marketing claims. The impact of future MRTP claims may depend on whether they are noticed, believed, and lead to smokers switching products. This study provides baseline data about smokers' exposure to perceived MRTP claims ahead of any MRTP authorizations. AIMS AND METHODS: We analyzed measures from Wave 3 of the US-based Population Assessment of Tobacco and Health (PATH) study which asked smokers to indicate if they had seen any e-cigarettes, snus, or other smokeless tobacco (SLT) products that claim to be "less harmful" in the past 12 months, and their likelihood of using products with these claims in the next 30 days. RESULTS: Significantly fewer smokers noted having seen snus (5.1%) or other SLT (5.6%) with "less harmful" claims compared with e-cigarettes (29.1%). For each product, the prevalence of MRTP claim exposure was higher among smokers who perceived the product to be less harmful than smoking, who currently used the product, and who had higher rates of tobacco advertising exposure at the point of sale. Among smokers who noticed products with "less harmful" claims, about one-quarter said they would use them in the future (24%-27%). CONCLUSIONS: Ahead of any Food & Drug Administration (FDA) authorization for MRTP claims, some smokers already perceive exposure to "less harmful" claims for e-cigarettes, but few do for SLT. MRTP claims may motivate some smokers to use these products. IMPLICATIONS: This study provides new baseline data about smokers' perceived exposure to MRTP claims in the United States ahead of any regulatory claim authorization. Using data from Wave 3 of the US PATH study, we found that some smokers already perceive exposure to "less harmful" claims for e-cigarettes (29%), but few do for SLT (5%-6%). Among smokers who noticed products with "less harmful" claims, about one-quarter said they would use them in the future (24%-27%), suggesting MRTP claims may motivate some smokers to use products described as "less harmful."
Authors: Geoffrey T Fong; Tara Elton-Marshall; Pete Driezen; Annette R Kaufman; K Michael Cummings; Kelvin Choi; Jonathan Kwan; Amber Koblitz; Andrew Hyland; Maansi Bansal-Travers; Charles Carusi; Mary E Thompson Journal: Addict Behav Date: 2018-11-17 Impact factor: 3.913
Authors: David T Levy; Elizabeth A Mumford; K Michael Cummings; Elizabeth A Gilpin; Gary Giovino; Andrew Hyland; David Sweanor; Kenneth E Warner Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-12 Impact factor: 4.254
Authors: Jennifer L Pearson; Amanda L Johnson; Sarah E Johnson; Cassandra A Stanton; Andrea C Villanti; Raymond S Niaura; Allison M Glasser; Baoguang Wang; David B Abrams; K Michael Cummings; Andrew Hyland Journal: Addiction Date: 2017-09-06 Impact factor: 6.526
Authors: David B Abrams; Allison M Glasser; Andrea C Villanti; Jennifer L Pearson; Shyanika Rose; Raymond S Niaura Journal: Prev Med Date: 2018-06-23 Impact factor: 4.018
Authors: Andrew Hyland; Bridget K Ambrose; Kevin P Conway; Nicolette Borek; Elizabeth Lambert; Charles Carusi; Kristie Taylor; Scott Crosse; Geoffrey T Fong; K Michael Cummings; David Abrams; John P Pierce; James Sargent; Karen Messer; Maansi Bansal-Travers; Ray Niaura; Donna Vallone; David Hammond; Nahla Hilmi; Jonathan Kwan; Andrea Piesse; Graham Kalton; Sharon Lohr; Nick Pharris-Ciurej; Victoria Castleman; Victoria R Green; Greta Tessman; Annette Kaufman; Charles Lawrence; Dana M van Bemmel; Heather L Kimmel; Ben Blount; Ling Yang; Barbara O'Brien; Cindy Tworek; Derek Alberding; Lynn C Hull; Yu-Ching Cheng; David Maklan; Cathy L Backinger; Wilson M Compton Journal: Tob Control Date: 2016-08-08 Impact factor: 7.552
Authors: David J Nutt; Lawrence D Phillips; David Balfour; H Valerie Curran; Martin Dockrell; Jonathan Foulds; Karl Fagerstrom; Kgosi Letlape; Anders Milton; Riccardo Polosa; John Ramsey; David Sweanor Journal: Eur Addict Res Date: 2014-04-03 Impact factor: 3.015
Authors: Maciej L Goniewicz; Danielle M Smith; Kathryn C Edwards; Benjamin C Blount; Kathleen L Caldwell; Jun Feng; Lanqing Wang; Carol Christensen; Bridget Ambrose; Nicolette Borek; Dana van Bemmel; Karen Konkel; Gladys Erives; Cassandra A Stanton; Elizabeth Lambert; Heather L Kimmel; Dorothy Hatsukami; Stephen S Hecht; Raymond S Niaura; Mark Travers; Charles Lawrence; Andrew J Hyland Journal: JAMA Netw Open Date: 2018-12-07
Authors: Kimberly G Wagoner; Beth A Reboussin; Jennifer Cornacchione Ross; Rachel Denlinger-Apte; John Spangler; Erin L Sutfin Journal: Addict Behav Date: 2022-05-07 Impact factor: 4.591
Authors: Julia C Chen-Sankey; Afton Kechter; Jessica Barrington-Trimis; Rob McConnell; Evan A Krueger; Tess Boley Cruz; Jennifer B Unger; Benjamin W Chaffee; Adam Leventhal Journal: Tob Control Date: 2021-05-31 Impact factor: 6.953
Authors: Olivia A Wackowski; Mariam Rashid; Kathryn L Greene; M Jane Lewis; Richard J O'Connor Journal: Int J Environ Res Public Health Date: 2020-09-18 Impact factor: 3.390